NervGen CEO Adam Rogers discussed why choosing a hand function endpoint for tetraplegia made sense for patients and how regulators…
On this week’s episode of the Business of Biotech, we talk with NervGen leaders Adam Rogers, M.D., and Rich Macary about NVG-291, a daily…
Advances in nerve regeneration. Tricking AI into believing in a fake disease. Mapping the Moon. All that and more in this week’s edition of The Prototype.
On this week’s BioTech Nation, Moira speaks with Dr. Adam Rogers, CEO of NervGen Pharma.
On this week’s BioTech Nation, Moira speaks with Dr. Adam Rogers, CEO of NervGen Pharma, about a new treatment that’s showing significant trial results for…
Dr. Adam Rogers spoke with Forbes about NVG-291 and the Phase 1b/2a CONNECT SCI Study.
Dr. Adam Rogers spoke with BioSpace about NVG-291 and the Phase 1b/2a CONNECT SCI Study.
